GeoVax Labs, Inc. 8-K

What Happened
GeoVax Labs, Inc. (GOVX) filed an 8-K reporting the results of its annual meeting of stockholders held June 17, 2026. The company received proxies totaling 1,288,684 of 2,892,570 issued and outstanding shares as of the April 20, 2026 record date (about 44.6%). There were 810,066 broker non‑votes (about 28.0% of outstanding shares) on several contested items. Stockholders elected a seven‑member slate of directors and approved multiple proposals including three Nasdaq-related approvals to permit issuance of shares upon exercise of warrants issued in February, March and May 2026, and ratified Wipfli LLP as the independent auditor.

Key Details

• Proxies received: 1,288,684 of 2,892,570 shares; broker non‑votes: 810,066.
• Director elections (for/withheld): Randal D. Chase 420,305 / 58,313; David A. Dodd 418,963 / 59,655; Dean G. Kollintzas 420,198 / 58,420; Nicole Lemerond 417,920 / 61,426; Robert T. McNally 419,481 / 59,137; Jayne Morgan 420,422 / 58,196; John N. Spencer, Jr. 420,434 / 58,184. All seven nominees were elected.
• Warrant issuance approvals (Nasdaq rule approvals):
  • February 2026 warrants: approval to issue up to 865,804 shares (vote: For 395,198; Against 65,103; Abstain 18,317).
  • March 2026 warrants: approval to issue up to 1,269,316 shares (vote: For 395,365; Against 66,838; Abstain 16,415).
  • May 2026 warrants: approval to issue up to 1,702,986 shares (vote: For 375,831; Against 35,336; Abstain 67,451).
  • Combined maximum issuable if all three warrant groups are exercised: up to 3,838,106 shares.
• Ratification of independent auditor: Wipfli LLP ratified (For 1,185,525; Against 37,409; Abstain 65,750).
• Advisory votes: Say‑on‑Pay approved (For 385,843; Against 65,826; Abstain 26,949). Advisory vote on frequency resulted in a three‑year cycle (1 Year 339,064; 2 Years 24,463; 3 Years 97,058; Abstain 18,033).

Why It Matters

• The election of the full board and ratification of the auditor maintain corporate governance continuity.
• Approval of the three Nasdaq warrant‑issuance proposals authorizes potential dilution: up to 3,838,106 additional shares could be issued upon exercise of those warrants, which is material for shareholders to monitor when assessing future share count and dilution.
• The advisory approval of executive compensation and the decision to hold say‑on‑pay votes every three years reflect shareholder sentiment and set the cadence for future advisory votes (non‑binding).

Investors should review the company’s full SEC filing for context on the warrants (terms, exercise prices and holders) and monitor any future filings for exercises or other equity changes.